Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Sir John Bell

- PMLiVE

Gilead’s Jyseleca is given a NICE recommendation for rheumatoid arthritis

JAK inhibitor approved for use in moderate-to-severe RA

- PMLiVE

NHS is set to begin offering COVID-19 vaccinations to over-70s this week

Announcement comes as ten new vaccination centres open in England

- PMLiVE

New NHS COVID-19 vaccination centres open as cases surge in the UK

NHS is aiming to vaccinate around 15 million people by mid-February

- PMLiVE

UK selects Shionogi’s Fetcroja for antimicrobial reimbursement scheme

The antibiotic treats infections caused by aerobic Gram-negative bacteria

- PMLiVE

NHS set to pilot GRAIL’s wide-ranging cancer blood test

Previous study indicates test can detect over 50 cancer types

- PMLiVE

Pierre Fabre’s Braftovi scores NICE backing for BRAF+ colorectal cancer

Drug approved in combination with Merck's KGaA's Erbitux

- PMLiVE

NHS asked to ‘ready’ itself to provide Pfizer’s COVID-19 vaccine

Health Secretary Matt Hancock expects widespread roll-out early next year

- PMLiVE

NICE launches consultation on its methods of drug evaluation

Public consultation launched on Friday 6 November

- PMLiVE

NHS gearing up for possible pre-Christmas COVID-19 vaccinations

NHS chief exec said the NHS is getting ready to administer vaccines

- PMLiVE

NICE – but not enough

Why evidence is better than assumption when executing commercial strategy

Webcast

Monitoring the impact of COVID-19 on the market access landscape

Research Partnership

Case study

Using qualitative conjoint to assess willingness-to-pay

Research Partnership

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links